ABBV · News · 20260917N

Oncology Pipeline Progress

AbbVie Inc. · 2026-09-17 · Importance 31 · Surprise 42

AbbVie reported that Phase 3 CERVINO results for etentamig met both dual primary endpoints—objective response rate and progression-free survival—in relapsed or refractory multiple myeloma. The results will be presented at the International Myeloma Society Annual Meeting in Glasgow, Scotland, from September 23 through September 26, 2026. Additional portfolio data will cover ABBV-2001 (ISB 2001), a trispecific T-cell engager, surzetoclax, a BCL-2 inhibitor, and combination approaches.

Key facts

• AbbVie announced new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. source
• Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches. source
• Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM). source